The goal of the Small Animal Imaging Lab (SAIL) Core Facility is to provide state-of-the art imaging resources to Moffitt Cancer Center (MCC) members for their basic and translational preclinical studies of rodent cancer models. The SAIL has expanded its services to offer a wide array of multimodality imaging, including MRI, hyperpolarized MRI, CT, PET, SPECT, beta particle, ultrasound, bioluminescence, and fluorescence imaging. These systems allow members to follow tumor development, progression, metastasis and the response to therapy in animal models using quantitative imaging. SAIL provides detection at high spatial resolution of a number of functional, metabolic and anatomical changes, including hypoxia, pH, temporal sensitivity to cellular density, blood flow, and glucose uptake and metabolism. These parameters can be quantified using SAIL's expertise in image feature extraction and analysis to generate an integrated analysis of tumor biology in situ. Animal tumor models are critical for understanding the biology of cancer and the complex responses of distinct tumor types to therapy. Imaging of these animal subjects is a core technology that can precisely define cancer behaviors. Further, as most of these modalities provided by the SAIL are available in the clinic, results with animal tumor models can be readily translated into clinical trials and clinical practice. Multimodality imaging is the key focus of the facility as this provides a broad range of technologies that assist members with their basic and pre-clinical research programs. Over the next funding period, the Specific Aims of the SAIL Core are to:
Aim 1. Assist members in experimental design, interpretation of results, and manuscript and grant preparation.
Aim 2. Provide and expand in vivo and ex vivo imaging and analytical technologies for research involving small animal cancer models.
Aim 3. Provide training and educational opportunities regarding small animal imaging technologies and approaches for members. During the previous award period, SAIL served members from three programs and contributed to 45 publications. In the most recent fiscal year, SAIL served 21 members, with 87% of total usage by peer-review- funded members. The SAIL uses a Laboratory Information Management System (LIMS) to consolidate usage tracking, scheduling, and billing functions. The LIMS also provides a secure repository for project and data management, which is accessible by members and their laboratory staff.
|Davis, Stacy N; Govindaraju, Swapamthi; Jackson, Brittany et al. (2018) Recruitment Techniques and Strategies in a Community-Based Colorectal Cancer Screening Study of Men and Women of African Ancestry. Nurs Res 67:212-221|
|Martínez, Úrsula; Brandon, Thomas H; Sutton, Steven K et al. (2018) Associations between the smoking-relatedness of a cancer type, cessation attitudes and beliefs, and future abstinence among recent quitters. Psychooncology 27:2104-2110|
|Perales-Puchalt, Alfredo; Perez-Sanz, Jairo; Payne, Kyle K et al. (2018) Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. J Leukoc Biol 103:799-805|
|Nelson, Ashley M; Jim, Heather S L; Small, Brent J et al. (2018) Sleep disruption among cancer patients following autologous hematopoietic cell transplantation. Bone Marrow Transplant 53:307-314|
|Singh, Kshipra; Coburn, Lori A; Asim, Mohammad et al. (2018) Ornithine Decarboxylase in Macrophages Exacerbates Colitis and Promotes Colitis-Associated Colon Carcinogenesis by Impairing M1 Immune Responses. Cancer Res 78:4303-4315|
|Kasting, Monica L; Giuliano, Anna R; Reich, Richard R et al. (2018) Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013-2015. Cancer Epidemiol Biomarkers Prev 27:503-513|
|Denson, Aaron; Burke, Nancy; Wapinsky, Georgine et al. (2018) Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol 41:133-139|
|Betts, Brian C; Bastian, David; Iamsawat, Supinya et al. (2018) Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A 115:1582-1587|
|Pidala, Joseph; Beato, Francisca; Kim, Jongphil et al. (2018) In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica 103:531-539|
|Hampras, S S; Tommasino, M; Zhao, Y et al. (2018) Cross-sectional associations between cutaneous viral infections and regulatory T lymphocytes in circulation. Br J Dermatol :|
Showing the most recent 10 out of 1254 publications